Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment and Prevention
Docetaxel is a commonly used taxane chemotherapeutic agent in the treatment of a variety of cancers, including breast cancer, ovarian cancer, prostate cancer, non-small cell lung cancer, gastric cancer, and head and neck cancer. Docetaxel exerts its anti-cancer effects through inhibition of the cell...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-09-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/31/9/423 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850261219403890688 |
|---|---|
| author | Aleymi M. Perez Nicole I. Haberland Mariya Miteva Tongyu C. Wikramanayake |
| author_facet | Aleymi M. Perez Nicole I. Haberland Mariya Miteva Tongyu C. Wikramanayake |
| author_sort | Aleymi M. Perez |
| collection | DOAJ |
| description | Docetaxel is a commonly used taxane chemotherapeutic agent in the treatment of a variety of cancers, including breast cancer, ovarian cancer, prostate cancer, non-small cell lung cancer, gastric cancer, and head and neck cancer. Docetaxel exerts its anti-cancer effects through inhibition of the cell cycle and induction of proapoptotic activity. However, docetaxel also impacts rapidly proliferating normal cells in the scalp hair follicles (HFs), rendering the HFs vulnerable to docetaxel-induced cell death and leading to chemotherapy-induced alopecia (CIA). In severe cases, docetaxel causes persistent or permanent CIA (pCIA) when hair does not grow back completely six months after chemotherapy cessation. Hair loss has severe negative impacts on patients’ quality of life and may even compromise their compliance with treatment. This review discusses the notable prevalence of docetaxel-induced CIA and pCIA, as well as their prevention and management. At this moment, scalp cooling is the standard of care to prevent CIA. Treatment options to promote hair regrowth include but are not limited to minoxidil, photobiomodulation (PBMT), and platelet-rich plasma (PRP). In addition, a handful of current clinical trials are exploring additional agents to treat or prevent CIA. Research models of CIA, particularly <i>ex vivo</i> human scalp HF organ culture and <i>in vivo</i> mouse models with human scalp xenografts, will help expedite the translation of bench findings of CIA prevention and/or amelioration to the clinic. |
| format | Article |
| id | doaj-art-6dc40a9facba4f848022856bf677d879 |
| institution | OA Journals |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-6dc40a9facba4f848022856bf677d8792025-08-20T01:55:28ZengMDPI AGCurrent Oncology1198-00521718-77292024-09-013195709572110.3390/curroncol31090423Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment and PreventionAleymi M. Perez0Nicole I. Haberland1Mariya Miteva2Tongyu C. Wikramanayake3Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL 33136, USADr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL 33136, USADr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL 33136, USADr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL 33136, USADocetaxel is a commonly used taxane chemotherapeutic agent in the treatment of a variety of cancers, including breast cancer, ovarian cancer, prostate cancer, non-small cell lung cancer, gastric cancer, and head and neck cancer. Docetaxel exerts its anti-cancer effects through inhibition of the cell cycle and induction of proapoptotic activity. However, docetaxel also impacts rapidly proliferating normal cells in the scalp hair follicles (HFs), rendering the HFs vulnerable to docetaxel-induced cell death and leading to chemotherapy-induced alopecia (CIA). In severe cases, docetaxel causes persistent or permanent CIA (pCIA) when hair does not grow back completely six months after chemotherapy cessation. Hair loss has severe negative impacts on patients’ quality of life and may even compromise their compliance with treatment. This review discusses the notable prevalence of docetaxel-induced CIA and pCIA, as well as their prevention and management. At this moment, scalp cooling is the standard of care to prevent CIA. Treatment options to promote hair regrowth include but are not limited to minoxidil, photobiomodulation (PBMT), and platelet-rich plasma (PRP). In addition, a handful of current clinical trials are exploring additional agents to treat or prevent CIA. Research models of CIA, particularly <i>ex vivo</i> human scalp HF organ culture and <i>in vivo</i> mouse models with human scalp xenografts, will help expedite the translation of bench findings of CIA prevention and/or amelioration to the clinic.https://www.mdpi.com/1718-7729/31/9/423docetaxelalopeciapreventionminoxidilscalp cooling |
| spellingShingle | Aleymi M. Perez Nicole I. Haberland Mariya Miteva Tongyu C. Wikramanayake Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment and Prevention Current Oncology docetaxel alopecia prevention minoxidil scalp cooling |
| title | Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment and Prevention |
| title_full | Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment and Prevention |
| title_fullStr | Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment and Prevention |
| title_full_unstemmed | Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment and Prevention |
| title_short | Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment and Prevention |
| title_sort | chemotherapy induced alopecia by docetaxel prevalence treatment and prevention |
| topic | docetaxel alopecia prevention minoxidil scalp cooling |
| url | https://www.mdpi.com/1718-7729/31/9/423 |
| work_keys_str_mv | AT aleymimperez chemotherapyinducedalopeciabydocetaxelprevalencetreatmentandprevention AT nicoleihaberland chemotherapyinducedalopeciabydocetaxelprevalencetreatmentandprevention AT mariyamiteva chemotherapyinducedalopeciabydocetaxelprevalencetreatmentandprevention AT tongyucwikramanayake chemotherapyinducedalopeciabydocetaxelprevalencetreatmentandprevention |